Physician profile
Ashraf Abdullah
NPI 1821006594
$4,667.23
in general payments reported to CMS, 2019-2025
42 companies · $135 in 2025
The $135 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,006 · 2020: $246 · 2021: $576 · 2022: $1,038 · 2023: $1,050 · 2024: $616 · 2025: $135.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,774 · Education: $26.93.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,774.26 |
| Education | $26.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $464.46 | 2020-2025 | Jardiance, Mounjaro, Zepbound |
| Pfizer INC. | $461.17 | 2019-2024 | |
| Novo Nordisk INC | $374.43 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Novartis Pharmaceuticals Corporation | $368.76 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $352.41 | 2019-2024 | Jardiance, Ofev |
| Glaxosmithkline, LLC. | $342.80 | 2020-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbvie INC. | $258.18 | 2021-2023 | Ubrelvy, Linzess, Vraylar |
| Astrazeneca Pharmaceuticals LP | $232.01 | 2019-2025 | Fasenra, Farxiga |
| Janssen Pharmaceuticals, INC | $204.79 | 2019-2021 | |
| Amgen INC. | $174.27 | 2022-2024 | Repatha, Otezla, Evenity |
| Dexcom, INC. | $128.86 | 2021-2024 | Dexcom G6 Transmitter |
| Abbott Laboratories | $107.94 | 2021-2024 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $101.87 | 2021-2023 | |
| E.R. Squibb & Sons, L.L.C. | $101.34 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $76.98 | 2021-2024 | Nuedexta, Rexulti |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashraf Abdullah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.